Fasting Blood Glucose Target in Type 2 Diabetes
For adults with type 2 diabetes, target a fasting blood glucose of 3.9-6.1 mmol/L (70-110 mg/dL), as this range optimally balances HbA1c achievement with hypoglycemia risk.
Treatment Strategy Framework
The 2024 ADA Standards of Care emphasize that pharmacologic therapy should be started at diagnosis and guided by a person-centered approach addressing glycemic control, weight management, and comorbidity-specific benefits 1.
Initial Pharmacologic Approach
Start with agents that address both glycemic and weight goals while considering comorbidities:
- Without cardiovascular/kidney disease: Select agents based on individualized glycemic and weight targets 1
- With heart failure (HFrEF or HFpEF): Use SGLT2 inhibitor for glycemic management and HF hospitalization prevention 1
- With CKD (eGFR 20-60 mL/min/1.73m² or albuminuria): Use SGLT2 inhibitor to minimize CKD progression, reduce cardiovascular events, and prevent HF hospitalizations 1
- With advanced CKD (eGFR <30 mL/min/1.73m²): Prefer GLP-1 RA for lower hypoglycemia risk and cardiovascular benefit 1
Optimal FBG Target Evidence
Research specifically examining FBG targets demonstrates that 3.9-6.1 mmol/L (70-110 mg/dL) is superior to both tighter (≤5.6 mmol/L) and looser (≤7.0 mmol/L) targets 2, 3:
- 46.1% of patients achieved HbA1c <7.0% with FBG target 3.9-6.1 mmol/L versus 37.7% with target ≤7.0 mmol/L (p=0.017) 2
- Hypoglycemia risk was acceptable: Alert hypoglycemia (glucose ≤3.9 mmol/L) occurred in 27.5% versus 23.3% in the looser target group (p=0.177), while clinically important hypoglycemia (≤3.0 mmol/L) remained low at 2.0% 2
- Glycemic variability improved significantly with the 6.1 mmol/L target compared to both tighter and looser targets 3
When to Intensify Treatment
Consider insulin initiation immediately if 1:
- Evidence of catabolism (unexpected weight loss)
- Symptomatic hyperglycemia
- A1C >10% (>86 mmol/mol) or blood glucose ≥300 mg/dL (≥16.7 mmol/L)
Medication Hierarchy
Before insulin, prefer GLP-1 RA (including dual GIP/GLP-1 RA) over insulin for superior weight and hypoglycemia profiles 1. Recent evidence shows these agents reduce cardiovascular events by 12-26%, heart failure by 18-25%, and kidney disease progression by 24-39% over 2-5 years 4.
If insulin is required:
- Combine with GLP-1 RA or dual GIP/GLP-1 RA for better glycemic control, weight outcomes, and reduced hypoglycemia 1
- Reassess and reduce sulfonylureas/meglitinides to minimize hypoglycemia risk 1
- Monitor for overbasalization: basal dose >0.5 units/kg/day, significant glucose differentials, or hypoglycemia episodes 1
Practical FBG-to-HbA1c Relationship
A simplified estimation: FBG of 100 mg/dL typically correlates with HbA1c ~6.0-6.5%, while FBG of 130 mg/dL approximates HbA1c ~7.0% 5. This relationship allows practical self-monitoring, though individual variation exists.
Common Pitfalls
- Avoiding early combination therapy: Consider starting dual therapy at diagnosis to reach targets faster 1
- Clinical inertia: Reassess medication plans every 3-6 months and adjust promptly 1
- Ignoring cost barriers: When financial constraints exist, use lower-cost options (metformin, sulfonylureas, human insulin) while weighing hypoglycemia and cardiovascular risks 1
- Targeting FBG too tightly: FBG <5.6 mmol/L increases hypoglycemia without improving HbA1c achievement 2